Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EBV Viremia”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Not applicableStudy completedNCT04189835
What this trial is testing

EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients

Who this might be right for
EBV InfectionEBV ViremiaEpstein-Barr Virus Associated Lymphoproliferative Disorder+1 more
University of Aarhus 509
Not applicableStudy completedNCT03546101
What this trial is testing

Early Detection of Epstein-Barr Virus Related Disease.

Who this might be right for
Post-transplant Lymphoproliferative DisorderMononucleosisEpstein-Barr Virus Infections+6 more
University of Aarhus 1,527
Testing effectiveness (Phase 2)Ended earlyNCT03283826
What this trial is testing

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Who this might be right for
Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Atara Biotherapeutics 134
Testing effectiveness (Phase 2)Ended earlyNCT03769467
What this trial is testing

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Who this might be right for
Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsEpstein-Barr Virus Infections+2 more
Atara Biotherapeutics 12
Testing effectiveness (Phase 2)Study completedNCT01329185
What this trial is testing

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

Who this might be right for
EBV ViremiaCMV Viremia
University of Minnesota 17
Testing effectiveness (Phase 2)Study completedNCT01498484
What this trial is testing

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Who this might be right for
EBV-induced LymphomasEBV-associated MalignanciesTransplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Atara Biotherapeutics 87
Not applicableNo Longer AvailableNCT02822495
What this trial is testing

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Who this might be right for
Epstein-Barr Virus (EBV) InfectionsLymphoproliferative DisordersEBV+ Associated Lymphoma+9 more
Atara Biotherapeutics
Testing effectiveness (Phase 2)Study completedNCT00002663
What this trial is testing

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Who this might be right for
EBV-induced LymphomasEBV-associated MalignanciesTransplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Atara Biotherapeutics 58
Not applicableStudy completedNCT03343834
What this trial is testing

Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Epstein-Barr ViraemiaHematologic DiseasesAllogeneic Disease
Assistance Publique - Hôpitaux de Paris 138
Not applicableStudy completedNCT06681025
What this trial is testing

Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients

Who this might be right for
EBV Viremia
QIAGEN Gaithersburg, Inc 1,070
Not applicableLooking for participantsNCT07294547
What this trial is testing

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Who this might be right for
Kidney Transplantation, Cytomegalovirus InfectionsEBV InfectionAntiviral Prophylaxis
National Taiwan University Hospital 80